Further understanding of when and where the DISC1/TRAX/GSK3β complex is formed and how the complex can be effectively dissembled by either GSK3β inhibitors or PKA activators (such as A2AR agonists or PDE4 inhibitors) would pave the way for developing new therapeutic agents for mental disorders. This evidence concerns the gene GSK3B and psychiatric disorder.